A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH ...
Medical Xpress on MSN13d
Asah1 Gene Identified as Potential Target for Treating Liver DiseaseResearchers identify the Asah1 gene as a promising target for novel therapies to treat nonalcoholic fatty liver disease ...
Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...
Non-alcoholic fatty liver disease has no early signs. Is your liver at risk? Expert reveals these simple tests could save your life!
Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic fatty liver diseases (NAFLD) into more severe forms of liver disease by ...
A fatty liver is the most common. Dr Sudeep Khanna, senior consultant, gastroenterology, Indraprastha Apollo Hospitals, ...
Otherwise, it would lead to diseases like acute (sudden) hepatitis (inflammation), chronic (long duration) hepatitis, fatty ...
Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...
Asian News International on MSN9d
Shilpa Medicare Secures SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid Tablets, Eyes Market Launch for NASHShilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational New Drug ...
The liver is essential for digestion, metabolism, detoxification, and fluid regulation. While alcohol abuse is a known cause ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback